Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15312382 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL471072 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL471069 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL19909853 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL8097423 | 0.69 | KDM1A (0.31) | — | |
| SCHEMBL11270878 | 0.61 | — | — | |
| Hydrochloric Acid SCHEMBL1864614 | 0.58 | ALDH1A1 (0.91) | ALDH1A1 | |
| SCHEMBL11539988 | 0.57 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL11539990 | 0.57 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL24895090 | 0.56 | ALDH1A1 (1.00) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Q6ZSR9, CUTA, MC4R | ALDH1A1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.